Future multicenter, prospective studies incorporating microbiological adjudication, adjustment for clinical confounders, and expanded biomarker panels (e.g., procalcitonin and IL-6) are required to clarify mechanisms and establish reliable infection risk models after PCI. This evidence concerns the gene IL6 and infection.